<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article248</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/TRIUMPH" style="display:block; margin-bottom:10px;">TRIUMPH Original</a></li>
<h2><strong>TRIUMPH</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria".The New England Journal of Medicine. 2006. 355(12):1233-1243.PubMed•Full text•PDF<br/>
<br/>
### Clinical Question<br/>
In patients with paroxysmal nocturnal hemoglobinuria (PNH), does eculizumab improve hemoglobin stabilization and reduce transfusion requirements?<br/>
<br/>
### Bottom Line<br/>
In patients with PNH, eculizumab significantly stabilized hemoglobin levels, reduced transfusion requirements, improved markers of intravascular hemolysis, and improved quality of life.<br/>
<br/>
### Major Points<br/><br/>
<br/>
### Guidelines<br/>
There are no direct guidelines outlined within this study. However, based on evidence from this trial, eculizumab may be a recommended treatment option for patients with PNH requiring frequent transfusions.<br/>
<br/>
### Design<br/>
- Double-blind, randomized, placebo-controlled, multicenter phase 3 trial<br/>
- N=87 patients with PNH<br/>
- Eculizumab group (n=43) vs. Placebo group (n=44)<br/>
- Treatment period of 26 weeks<br/>
- Two primary endpoints: stabilization of hemoglobin levels without transfusion, number of units of packed red cells transfused<br/>
- Secondary endpoints included changes in lactate dehydrogenase levels and quality of life measures.<br/>
<br/>
### Population<br/>
- Adults (≥18 years) with PNH with at least four transfusions in the prior 12 months.<br/>
- Inclusion: PNH type III erythrocyte proportion ≥ 10%, platelet count ≥100,000/mm3, lactate dehydrogenase ≥1.5 times the upper limit of normal.<br/>
- Exclusion: Recent investigational drug use, complement deficiency, active bacterial infection, or history of bone marrow transplantation.<br/>
<br/>
### Interventions<br/>
- Eculizumab: 600 mg intravenously weekly for 4 weeks, followed by 900 mg at week 5 and then 900 mg biweekly through week 26.<br/>
- Placebo administered with the same schedule.<br/>
<br/>
### Outcomes<br/>
#### Primary Outcomes<br/>
- Stabilization of hemoglobin levels without transfusion: 49% in eculizumab group vs. 0% in placebo (P&lt;0.001).<br/>
- Units of packed red cells transfused: Median of 0 units in eculizumab group vs. 10 units in placebo (P&lt;0.001).<br/>
<br/>
#### Secondary Outcomes<br/>
- Transfusion independence was achieved in 51% with eculizumab vs. 0% with placebo (P&lt;0.001).<br/>
- 85.8% lower median area under the curve for lactate dehydrogenase in eculizumab group (P&lt;0.001).<br/>
- FACIT-Fatigue instrument and EORTC QLQ-C30 scores improved significantly from baseline to week 26 compared to placebo (P&lt;0.001).<br/>
<br/>
### Criticisms<br/>
- Lack of long-term outcome data regarding eculizumab's effect on thrombosis incidence in PNH.<br/>
- Results may not be generalizable to PNH patients without a history of frequent transfusions.<br/>
<br/>
### Funding<br/>
- Funded by Alexion Pharmaceuticals.<br/>
- Several authors reported financial relationships with Alexion Pharmaceuticals.<br/>
<br/>
### Further Reading<br/>
- Supplemental materials and full trial protocol available on study publication page.<br/>
- Additional research and long-term studies on the use of eculizumab in PNH.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
